基因疗法开发商BioMarin宣布完成对Alesta Therapeutics的收购-动脉网

BioMarin Announces Close of the Alesta Therapeutics Acquisition

CISION 等信源发布 2026-09-01 21:05



可切换为仅中文







Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline

收购为临床管线增添了ALE1，这是一种潜在的为首个治疗低磷酸酶症的口服疗法

SAN RAFAEL, Calif.

加利福尼亚州圣拉斐尔

，

Sept. 1, 2026

2026年9月1日

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:

/美通社/ -- BioMarin Pharmaceutical Inc.（纳斯达克：

BMRN

) said today that it completed the previously announced agreement to acquire Alesta Therapeutics. The acquisition will strengthen BioMarin's skeletal conditions portfolio, adding ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene.

）今日宣布，已完成此前公布的收购Alesta Therapeutics的协议。此次收购将加强BioMarin在骨骼疾病领域的产品组合，新增ALE1——一种用于潜在治疗低磷酸酯酶症（HPP）的口服小分子药物。低磷酸酯酶症是一种由ALPL基因突变引起的罕见遗传性骨病。

ALE1 is currently being evaluated in an ongoing Phase 1/2a clinical trial assessing safety, tolerability and pharmacokinetics/pharmacodynamics in healthy volunteers and adults with HPP..

ALE1 正在一项正在进行的 1/2a 期临床试验中接受评估，该试验旨在评估其在健康志愿者和成人低磷酸酯酶症（HPP）患者中的安全性、耐受性以及药代动力学/药效学特征。

On August 18, BioMarin announced it had entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1. Prior to the close of the transaction, Alesta spun out all non-ALE1 assets to a new entity. Alesta Therapeutics is now a wholly owned subsidiary of BioMarin..

8月18日，BioMarin宣布已签订最终协议，收购Alesta Therapeutics，以获得其核心临床阶段资产ALE1。在交易完成前，Alesta将所有非ALE1资产剥离至一家新实体。目前，Alesta Therapeutics已成为BioMarin的全资子公司。

About BioMarin

关于BioMarin

BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

BioMarin 是一家领先的全球罕见病生物技术公司，致力于为患有遗传性疾病的患者提供药物。该公司成立于1997年，总部位于加利福尼亚州圣拉斐尔，拥有良好的创新记录，目前有九种商业化疗法，并拥有强大的临床和临床前研发管线。

Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients..

BioMarin 采用独特的药物研发方法，致力于通过开发具有深远患者影响的开创性药物，充分释放遗传科学的潜力。

To learn more, please visit

欲了解更多信息，请访问

www.biomarin.com

。

About Alesta Therapeutics

关于Alesta Therapeutics

Alesta Therapeutics is a clinical-stage biotechnology company committed to developing novel oral small-molecule therapies for underserved diseases. The company's lead asset, ALE1, is being developed for hypophosphatasia (HPP), a rare genetic disorder with significant unmet need.

Alesta Therapeutics 是一家临床阶段的生物技术公司，致力于开发针对未满足医疗需求疾病的新型口服小分子疗法。公司的核心资产 ALE1 正在针对低磷酸酯酶症（HPP）进行开发，这是一种存在巨大未满足医疗需求的罕见遗传性疾病。

For more information, visit

欲了解更多信息，请访问

www.alestatherapeutics.com

。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements about, among other things, the acquisition of

本新闻稿包含有关收购的前瞻性陈述，其中包括

ALE1, the lead clinical-stage asset, of Alesta

Alesta 的主要临床阶段资产 ALE1

Therapeutics (Alesta) by BioMarin Pharmaceutical Inc. (BioMarin) and the business prospects of BioMarin, including, without limitation, statements about: the prospective benefits of the acquisition, including expectations that it will strengthen BioMarin's skeletal conditions portfolio

BioMarin Pharmaceutical Inc.（BioMarin）收购 Therapeutics（Alesta）以及 BioMarin 的业务前景，包括但不限于以下陈述：此次收购的预期收益，包括预计将加强 BioMarin 在骨骼疾病领域的产品组合

;

；

expectations regarding ALE1 and its ongoing development, including its

关于ALE1及其持续发展的预期，包括其

potential to be a first-in-class oral therapy for the treatment of hypophosphatasia (HPP);

有望成为首个用于治疗低磷酸酯酶症（HPP）的同类首创口服疗法；

and other statements that are not historical facts.

以及其他非历史事实的陈述。

These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the effects of the acquisition (or the announcement thereof) on BioMarin's stock price and/or BioMarin's operating results; unknown or inestimable liabilities; BioMarin's ability to successfully develop, launch and commercialize products and product candidates such as ALE1, if approved; BioMarin's ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period and that integration will not be successful or that such integration may be more difficult, time-consuming or costly than expected; the time-consuming and uncertain regulatory approval process for pharmaceutical product development; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients, including with respect to current and planned future clinical trials; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption 'Risk Factors' in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as such factors may be updated by any subsequent reports.

这些前瞻性陈述属于预测性质，涉及风险和不确定性，因此实际结果可能与这些陈述存在重大差异。这些风险和不确定性包括但不限于：收购（或相关公告）对BioMarin股价和/或经营业绩的影响；未知或难以估量的负债；BioMarin成功开发、推出并将产品（如ALE1，若获批准）及候选产品商业化的能力；BioMarin实现收购预期效益的能力，包括预期效益可能无法实现或未在预期时间内实现、整合可能不成功，或整合过程可能比预期更困难、更耗时或成本更高的可能性；药品开发监管审批过程的耗时性和不确定性；药品开发过程的高成本和耗时性，以及临床成功的不确定性，包括与未能成功启动或完成临床试验或患者评估相关的风险或延迟（包括当前和计划中的未来临床试验）；以及BioMarin向美国证券交易委员会提交的文件中详述的那些因素，包括但不限于BioMarin截至2026年6月30日的季度10-Q报表中“风险因素”标题下所列的因素，且这些因素可能因后续报告而更新。

Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any fo.

投资者被敦促不要过度依赖前瞻性陈述，这些陈述仅反映截至本文发布之日的情况。BioMarin 没有义务，并且明确声明没有任何义务去更新或修改任何前瞻性陈述。

BioMarin

拜玛林

注册商标符号

is a registered trademark of BioMarin Pharmaceutical Inc. or its affiliates.

是 BioMarin Pharmaceutical Inc. 或其关联公司的注册商标。

Contacts:

联系人：

Investors

投资者

Media

媒体